▪ Covers 116 genes related to targeted therapy for solid tumor that have been approved by FDA/NMPA, recommended in NCCN guidelines, or have shown clinically significant potential in clinical trials, and evaluates multiple targeted drugs for solid tumor that have been approved or in phase II/III clinical trials

▪ Covers genes related to multiple signaling pathways for tumor occurrence and development

▪ Covers 40 (37 in the blood/body fluid edition) HRR genes. Combined with HRD score test, it comprehensively assesses HRD status and the efficacy of PARP inhibitors

▪ Has the only neoantigen algorithm in China validated by the Tumor Neoantigen Selection Alliance (TESLA)

▪ The blood edition/body fluid edition bTMB uses a machine learning model, which is highly consistent with the tissue TMB (0.90)

▪ Covers 109 chemotherapy genes related to Asian/Chinese populations and assesses the efficacy and toxicity risks of chemotherapy drugs

▪ The mutation information is accurately described according to the HGVS standard terms. The germline genetic mutations are classified according to the ACMG guidelines for the classification of the pathogenicity of mutations, and the clinical medication is suggested based on clinical based medical evidence

▪ Ultra-high depth sequencing and the limit of detection of ctDNA is 0.1%

▪ Covers gene germline interpretation and prompts genetic risks